revealed that MUC1 peptide vaccines elicited significant immune responses in a subset of adenoma patients, with 25% showing at least a twofold increase in MUC1 IgG levels after 12 weeks, correlating with reduced adenoma recurrence rates and suggesting MUC1’s role in immune surveillance for intestinal adenoma prevention (179). This evidence concerns the gene MUC1 and adenoma.